Abstract
Tocilizumab has been recognized as one of the few existing biologic useful for combating COVID-19 infections especially in critically ill patient. We had experience in treating five critically ill patients with severe lung injury who were COVID-19 positive with tocilizumab. In the present case series, we have attempted to summarize their clinical profile, changes in laboratory biomarkers and outcomes.
All Keywords
【초록키워드】 COVID-19, Tocilizumab, outcomes, Case series, Critically ill, COVID-19 infection, Patient, biologic, Critically ill patient, positive, FIVE, severe lung injury, combating, changes in, laboratory biomarker, 【제목키워드】 Tocilizumab, Infection, Critically ill, with COVID-19,
【초록키워드】 COVID-19, Tocilizumab, outcomes, Case series, Critically ill, COVID-19 infection, Patient, biologic, Critically ill patient, positive, FIVE, severe lung injury, combating, changes in, laboratory biomarker, 【제목키워드】 Tocilizumab, Infection, Critically ill, with COVID-19,